Why ARTHEx Biotech’s ATX-01 update could reshape RNA-targeted therapy in myotonic dystrophy
Find out how ARTHEx Biotech’s ATX-01 data could reshape RNA-targeted therapy for myotonic dystrophy today!
What PepGen’s 5 mg/kg FREEDOM2 cohort reveals about the risk-reward profile of PGN-EDODM1
PepGen’s FREEDOM2 data hint at PGN-EDODM1 activity in DM1, but bigger questions remain. Read what the 5 mg/kg cohort really changes.